These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27406083)

  • 21. Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy.
    Harms MH; van Buuren HR; van der Meer AJ
    Best Pract Res Clin Gastroenterol; 2018; 34-35():85-94. PubMed ID: 30343714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Not Available].
    Vetter C
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():56. PubMed ID: 26048128
    [No Abstract]   [Full Text] [Related]  

  • 23. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
    Akepati PR; Gochanour EM
    Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modern treatment of primary biliary cholangitis].
    Strassburg CP
    Internist (Berl); 2018 Jan; 59(1):105-112. PubMed ID: 29110023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geoepidemiology and changing mortality in primary biliary cholangitis.
    Floreani A; Tanaka A; Bowlus C; Gershwin ME
    J Gastroenterol; 2017 Jun; 52(6):655-662. PubMed ID: 28365879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary Biliary Cholangitis: advances in management and treatment of the disease.
    Invernizzi P; Floreani A; Carbone M; Marzioni M; Craxi A; Muratori L; Vespasiani Gentilucci U; Gardini I; Gasbarrini A; Kruger P; Mennini FS; Ronco V; Lanati E; Canonico PL; Alvaro D
    Dig Liver Dis; 2017 Aug; 49(8):841-846. PubMed ID: 28546061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New treatment options for primary biliary cholangitis].
    Keitel-Anselmino V; Nitschmann S
    Inn Med (Heidelb); 2024 Sep; 65(9):962-964. PubMed ID: 39167191
    [No Abstract]   [Full Text] [Related]  

  • 28. In Search of the Best Second-Line Therapy for Primary Biliary Cholangitis.
    Lens S
    Gastroenterology; 2024 Aug; 167(3):623-624. PubMed ID: 38387599
    [No Abstract]   [Full Text] [Related]  

  • 29. Current and potential treatments for primary biliary cholangitis.
    Shah RA; Kowdley KV
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving role of obeticholic acid in primary biliary cholangitis.
    Levy C
    Hepatology; 2018 May; 67(5):1666-1668. PubMed ID: 29222924
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel Therapies in Primary Biliary Cholangitis: What Is in the Pipeline?
    Buchanan-Peart KA; Levy C
    Clin Liver Dis; 2022 Nov; 26(4):747-764. PubMed ID: 36270727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
    Bowlus CL; Pockros PJ; Kremer AE; Parés A; Forman LM; Drenth JPH; Ryder SD; Terracciano L; Jin Y; Liberman A; Pencek R; Iloeje U; MacConell L; Bedossa P
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1170-1178.e6. PubMed ID: 31606455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.
    Fiorucci S; Urbani G; Di Giorgio C; Biagioli M; Distrutti E
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
    Silveira MG; Lindor KD
    Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment.
    MacDonald N; Loh R; Fenkel JM; Sass DA; Halegoua-DeMarzio D
    BMC Gastroenterol; 2024 Jan; 24(1):18. PubMed ID: 38178006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Farnesoid X receptor agonists for primary biliary cirrhosis.
    Lindor KD
    Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
    Trauner M; Nevens F; Shiffman ML; Drenth JPH; Bowlus CL; Vargas V; Andreone P; Hirschfield GM; Pencek R; Malecha ES; MacConell L; Shapiro D
    Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):445-453. PubMed ID: 30922873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs for the treatment of primary biliary cholangitis.
    Phaw NA; Dyson JK; Jones D
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.